Cancer Patients' blood thinner mystery solved?
NCT ID NCT05819736
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study measured how two common blood thinners (rivaroxaban and apixaban) behave in 193 adults with active cancer who also had blood clots or atrial fibrillation. Researchers aimed to understand factors like age, weight, and kidney function that affect drug levels. The goal was to gather real-world data to guide safer use of these medications in cancer patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTICOAGULANTS AND THROMBOTIC DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre d'Investigation Clinique Hôpital Pitié-Salpêtrière
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare
- Can simple positive activities boost Well-Being in cancer care?